A phase Ib/II trial testing a combination of capmatinib and gefitinib in patients with EGFR-mutated NSCLC that developed resistance to EGFR TKIs showed encouraging results, particularly in tumors with high MET gene copy number [139]. The gene discussed is MET; the disease is non-small cell lung carcinoma.